Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00246987 · ClinicalTrials.gov registry record · Phase 3
A Trial to Evaluate BMS-298585 as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 341
- Enrollment target
NCT00246987 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 341 participants.
The verdict
NCT00246987, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 341 participants
- Enrollment target
Study Summary
To determine the effect on glycemic control and lipid parameters of the 2.5 and 5 mg. doses of BMS-298585 in drug naive subjects with Type 2 diabetes as an adjunct to diet and exercise.
Interventions
- DRUG Muraglitazar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 341 participants |
| Start Date | 2003-06 |
| Est. Completion | 2004-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00246987
The ClinicalTrials.gov registry entry for NCT00246987 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 341 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Muraglitazar is the first listed.
NCT00246987 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00246987 about?
NCT00246987 is a clinical study titled "A Trial to Evaluate BMS-298585 as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control". To determine the effect on glycemic control and lipid parameters of the 2.5 and 5 mg. doses of BMS-298585 in drug naive subjects with Type 2 diabetes as an adjunct to diet and exercise.
What is the current status of trial NCT00246987?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 341 participants. The study started on 2003-06. Estimated completion is 2004-04.
What interventions are being tested in trial NCT00246987?
The interventions under investigation include: Muraglitazar (DRUG).
Who is sponsoring clinical trial NCT00246987?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.